BGM Group (NASDAQ:BGM) Stock Price Down 12.4% – What’s Next?

Shares of BGM Group Ltd. (NASDAQ:BGM) were down 12.4% on Wednesday . The company traded as low as $0.2830 and last traded at $0.2899. Approximately 260,108 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 565,652 shares. The stock had previously closed at $0.3310.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of BGM Group in a report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, BGM Group has a consensus rating of “Sell”.

BGM Group Trading Down 12.4%

The company has a fifty day moving average of $1.05 and a two-hundred day moving average of $5.04.

Institutional Investors Weigh In On BGM Group

Several hedge funds have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in shares of BGM Group during the 2nd quarter valued at $218,000. Mariner LLC acquired a new stake in shares of BGM Group during the 3rd quarter valued at $267,000. Finally, Geode Capital Management LLC acquired a new stake in shares of BGM Group during the 2nd quarter valued at $412,000.

BGM Group Company Profile

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.